IP Library Granted Patent US 8,029,784
Granted Patent B2
US 8,029,784 · App. 12/041,969 · Granted Oct 4, 2011

Method for the diagnosis and prognosis of malignant diseases

Assignee: University of Louisville Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,029,784
App. No.
12/041,969
Granted
Oct 4, 2011
Kind
B2
Abstract

Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.

Claims (7)

1. A method of treating cancer in a subject comprising administering to said subject a therapeutically effective amount of an anti-nucleolin antibody and a pharmaceutically acceptable carrier, wherein said nucleolin antibody is substantially non-immunogenic to human.

2. The method of claim 1 , further comprising administering to said subject a chemotoxic or chemotherapeutic agent.

3. The method of claim 1 , further comprising treating said subject with radiation therapy.

4. The methods of claim 2 wherein said chemotoxic or chemotherapeutic agent is selected from the group consisting of cyclophosphamide, etoposide, doxorubicin, methotrexate, vincristine, procabazine, prednisone, dexamethasone, tamoxifen citrate, carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, zoledronic acid, Ibandronate and mytomicin.

5. A method of treating cancer in a subject comprising administering to said subject a therapeutically effective amount of an antinucleolin antibody, a chemotoxic or chemotherapeutic agent and a pharmaceutically acceptable carrier.

6. The method of claim 5 , wherein said chemotoxic or chemotherapeutic agent is selected from the group consisting of cyclophosphamide, etoposide, doxorubicin, methotrexate, vincristine, procabazine, prednisone, dexamethasone, tamoxifen citrate, carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, zoledronic acid, Ibandronate and mytomicin.

7. A method of treating cancer in a subject comprising administering to said subject a therapeutically effective amount of an antinucleolin antibody and a pharmaceutically acceptable carrier, and further treating said subject with radiation therapy.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 14, 2016
From: UNIVERSITY OF LOUISVILLE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038992/0265 →
Continuity (3)
Continuation 10683480 · Oct 9, 2003
Continuation In Part 10118854 · Apr 8, 2002
Related Publication 20090017009A1 · Jan 15, 2009